| ²é¿´: 439 | »Ø¸´: 2 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
µ¥¾äÇóÖú
|
|
| In summary, in recent years DLL4 has appeared as a significant regulator of tumor angiogenesis. Blockade of this ligand results in non-productive angiogenesis with an inhibitory effect on tumor growth. Nevertheless, the careful evaluation of adverse effects on physiology of normal organs in relation to therapeutic doses of DLL4 inhibitors will be critical for advancement of DLL4 blocking agents in clinical oncology. |
» ²ÂÄãϲ»¶
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ5È˻ظ´
081700£¬311£¬Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ18È˻ظ´
²ÄÁÏÓ뻯¹¤371Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
336²ÄÁÏÓ뻯¹¤085600Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁÏ334Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
331Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏר˶322
ÒѾÓÐ7È˻ظ´

xux730
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 86
- Ó¦Öú: 1719 (½²Ê¦)
- ½ð±Ò: 10740.4
- É¢½ð: 50
- ºì»¨: 43
- Ìû×Ó: 2947
- ÔÚÏß: 336.5Сʱ
- ³æºÅ: 1374299
- ×¢²á: 2011-08-20
- רҵ: ϸ°ûÖÜÆÚÓëµ÷¿Ø
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
yin198716: ½ð±Ò+5, ·ÒëEPI+1 2013-09-23 23:44:16
yin198716: ½ð±Ò+5, ·ÒëEPI+1 2013-09-23 23:44:16
| ×ÜÖ®£¬ÔÚ×î½ü¼¸ÄêÖÐDLL4Ã÷ÏÔ³ÉΪÖ×ÁöѪ¹ÜÉú³ÉµÄÒ»¸öÏÔÖøµ÷½ÚÒò×Ó¡£×è¶Ï¸ÃÅäÌåµ¼Ö¶ÔÖ×ÁöÉú³¤¾ßÓÐÒÖÖÆÐ§¹ûµÄÎÞЧѪ¹ÜÉú³É¡£È»¶ø£¬×ÐϸÆÀ¹ÀÖÎÁƼÁÁ¿µÄDLL4ÒÖÖÆ¼Á¶ÔÕý³£Æ÷¹ÙÉúÀíÉϵIJ»Á¼Ó°Ï콫ÊÇDLL4×è¶Ï¼ÁÔÚÁÙ´²Ö×ÁöѧȡµÃ½øÕ¹µÄ¹Ø¼ü¡£ |
2Â¥2013-09-23 22:04:15
ÕŹúÓª2176
гæ (СÓÐÃûÆø)
- Ó¦Öú: 4 (Ó×¶ùÔ°)
- ½ð±Ò: 144.9
- Ìû×Ó: 57
- ÔÚÏß: 15.9Сʱ
- ³æºÅ: 2441457
- ×¢²á: 2013-04-29
- רҵ: ¹Ç¡¢¹Ø½Ú¡¢Èí×éÖ¯ËðÉËÓëÐÞ
3Â¥2013-09-23 23:00:35














»Ø¸´´ËÂ¥
5